Table 1.
Reported strategies for modulation of drug release from silicone elastomers.
| Strategy | Mechanism | Description | References |
|---|---|---|---|
| Incorporation of hydrophilic excipients | Introduce pores to create water channels | HPMC, sucrose, or glycine dispersed in silicone to increase bovine serum albumin (BSA) release | Carelli et al. 1989; Woolfson et al. 2006; Brook et al. 2008; Di Colo 1992; Morrow et al. 2011; Snorradóttir et al. 2011; Murphy et al. 2016; Mazurek et al. 2018; McBride, Boyd, et al. 2019; Mazurek, Frederiksen, et al. 2021; Mazurek, Yuusuf, et al. 2021 |
| Hydrophilic polymer blending | Blend silicone with polymers to enhance water uptake and drug mobility | Silicone–polyethylene glycol (PEG) copolymer matrices used to enhance the permeability of the silicone elastomer to hydrophilic and ionic species | Li and Peck 1989; Rajendra et al. 2010; Forbes et al. 2014; Mikolaszek et al. 2020 |
| Porous matrix | Introduction of pores to promote diffusion | Silicone containing PEG8000-leached pores to enhance acetaminophen and tartrazine release | Dahl and Sue 1992; Nemati et al. 2014 |
| Use of co-solvents or solubilizers | Enhancing drug mobility by reducing matrix–drug interactions and lowering diffusion activation energy | Glycerol and NaCl incorporated into silicone elastomer implants to enhance release of melatonin and estradiol | Hsieh et al. 1985; Maeda, Brandon, et al. 2003 |
| Incorporation of preformed hydrogel particles | Embedding hydrophilic hydrogel particles that swell upon hydration to form aqueous diffusion paths | Polyacrylamide hydrogel particles incorporated in silicone rubber to enhance progesterone release | Lopour et al. 1990; Mashak 2008 |
| Drug molecular complexation | Modify drug solubility and partitioning via inclusion complexation | Azelaic acid-hydroxypropyl-β-cyclodextrin complex used in silicone membrane to enhance the release of azelaic acid | Manosroi et al. 2005 |
| Surface hydrophilization | Graft hydrophilic groups on silicone surface | PEGylation of silicone elastomer to modulate triclosan release | McBride et al. 2009 |
| Drug particle size engineering | Altering particle size to modify surface area and diffusion dynamics | Larger particle size of interferon/human serum albumin (HSA) powder in silicone elastomer to increase release rate of IFN | Kajihara et al. 2000; Farahmandghavi et al. 2019 |
| Polymer microstructure engineering | Using additives/fillers to modify polymer crystallinity, viscosity, drug affinity, and diffusion paths | Silica, PEG, or silicone oil used to modify polydimethylsiloxanes for optimized levonorgestrel release | McConville et al. 2012; Tolia and Li 2012; Ma et al. 2018; Fanse et al. 2024 |
| Formulation geometry design | Control of release via physical structure to maintain a constant diffusion area | A 1/8 fractional segment core design of vaginal ring to achieve zero-order release of oxybutynin | Kajihara et al. 2001, 2003; Maeda, Ohashi, et al. 2003; Woolfson et al. 2003 |
| Stimuli-responsive additives | Triggering release via stimuli, such as pH, enzymes, or temperature | N-isopropylacrylamide hydrogel particles incorporated into a silicone rubber membrane as temperature-responsive additives that enhance release at temperature > 34 °C | Hu et al. 2000; Nemati et al. 2014 |